Biogen Inc (BIIB.OQ)
346.39USD
8:01pm BST
$3.46 (+1.01%)
$342.93
$341.00
$346.78
$339.21
182,767
680,969
$388.67
$249.24
About
Overall
| Beta: | 0.72 |
| Market Cap(Mil.): | $69,239.67 |
| Shares Outstanding(Mil.): | 211.43 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| BIIB.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 21.50 | 30.93 | 32.76 |
| EPS (TTM): | 15.23 | -- | -- |
| ROI: | 17.59 | 15.07 | 14.61 |
| ROE: | 28.64 | 16.59 | 16.33 |
Biogen's pricey muscle drug Spinraza too costly for Britain
LONDON Biogen's muscle disease treatment Spinraza has been deemed too expensive for use on Britain's state-run health service, even after a price discount offered by the U.S. drugmaker.
Biogen's pricey muscle drug Spinraza too costly for Britain
LONDON Biogen's muscle disease treatment Spinraza has been deemed too expensive for use on Britain's state-run health service, even after a price discount offered by the U.S. drugmaker.
Biogen's pricey muscle drug Spinraza too costly for Britain
LONDON, Aug 14 Biogen's muscle disease treatment Spinraza has been deemed too expensive for use on Britain's state-run health service, even after a price discount offered by the U.S. drugmaker.
Eisai shares fall 18 pct after release of Alzheimer drug test details
TOKYO, July 26 Shares of Japanese drugmaker Eisai fell more than 18 percent on Thursday after the company and its partner Biogen Inc presented the details of their experimental drug on Alzheimer's disease. (Reporting by Hideyuki Sano; Editing by Stephen Coates)
Biogen/Eisai Alzheimer's drug cut cognitive decline by 30 pct -study
CHICAGO, July 25 Biogen Inc and partner Eisai Co Ltd said patients with early-stage Alzheimer's disease treated with their experimental drug BAN2401 experienced 30 percent less cognitive decline than patients who got a placebo in a highly anticipated midstage trial.
Biogen easily tops Street estimates on Spinraza sales, raises forecast
Biogen Inc reported far better-than-expected second quarter profit on Tuesday, driven by strong demand of its Spinraza muscle disease treatment, and the U.S. biotech company raised its full-year profit forecast.
REFILE-UPDATE 3-Biogen easily tops Street estimates on Spinraza sales, raises forecast
* Late-stage trials for Alzheimer's drug aducanumab fully enrolled
Biogen quarterly sales rise 9 pct
July 24 Biogen Inc reported a 9 percent rise in quarterly revenue on Tuesday, helped by demand for its spinal muscular atrophy drug Spinraza.
U.S. jobs growth lifts Wall Street, offsetting tariffs
NEW YORK U.S. stocks climbed on Friday, with the S&P 500 and the Nasdaq hitting their highest levels in two weeks, as strong U.S. jobs growth blunted the impact of an escalating U.S.-China trade dispute. | Video
CORRECTED-US STOCKS-U.S. jobs growth lifts Wall Street, offsetting tariffs
NEW YORK, July 6 U.S. stocks climbed on Friday, with the S&P 500 and the Nasdaq hitting their highest levels in two weeks, as strong U.S. jobs growth blunted the impact of an escalating U.S.-China trade dispute.
Competitors
| Price | Chg | |
|---|---|---|
| Johnson & Johnson (JNJ.N) | $134.71 | +2.23 |
| Pfizer Inc. (PFE.N) | $42.10 | +0.68 |
| Novartis AG (NOVN.S) | CHF82.48 | +0.76 |
| Merck & Co., Inc. (MRK.N) | $69.01 | +0.17 |
| Roche Holding Ltd. (ROG.S) | CHF239.95 | +0.75 |
| Roche Holding Ltd. (RO.S) | CHF243.20 | +0.20 |
| Bayer AG (BAYGn.DE) | €78.40 | +1.35 |
| Bayer AG (BAYE.F) | -- | -- |
| Sanofi SA (SASY.PA) | €73.30 | +0.64 |
| GlaxoSmithKline plc (GSK.L) | 1,617.00 | +7.00 |
Estimates